Design, Synthesis and Biological Evaluation of New N‐Acyl Hydrazones with a Methyl Sulfonyl Moiety as Selective COX‐2 Inhibitors

The mechanism of action of nonsteroidal anti‐inflammatory drugs (NSAIDs) is inhibition of specific prostaglandin (PG) synthesis by inhibition of cyclooxygenase (COX) enzymes. The two COX isoenzymes show 60 % similarity. It is known that the nonspecific side effects of conventional NSAIDs are physiologically caused by inhibition of the COX‐1 enzyme. Therefore, the use of COX‐2 selective inhibitors is seen to be a more beneficial approach in reducing these negative effects. However, some of the existing COX‐2 selective inhibitors show cardiovascular side effects. Therefore, studies on the development of new selective COX‐2 inhibitors remain necessary. It is important to develop new COX‐2 inhibitors in the field of medicinal chemistry. Accordingly, novel N‐acyl hydrazone derivatives were synthesized as new COX‐2 inhibitors in this study. The hydrazone structure, also known for its COX activity, is important in terms of many biological activities and was preferred as the main structure in the design of these compounds. A methyl sulfonyl pharmacophore was added to the structure in order to increase the affinity for the polar side pocket present in the COX‐2 enzyme. It is known that methyl sulfonyl groups are suitable for polar side pockets. The synthesis of the compounds (3a–3j) was characterized by spectroscopic methods. Evaluation of in vitro COX‐1/COX‐2 enzyme inhibition was performed by fluorometric method. According to the enzyme inhibition results, the obtained compounds displayed the predicted selectivity for COX‐2 enzyme inhibition. Compound 3j showed important COX‐2 inhibition with a value of IC50=0.143 uM. Interaction modes between the COX‐2 enzyme and compound 3j were investigated by docking studies.

[1]  Serkan Levent,et al.  Design, synthesis, biological evaluation, and docking studies of some novel chalcones as selective COX‐2 inhibitors , 2020, Archiv der Pharmazie.

[2]  Serkan Levent,et al.  Design, synthesis and biological assessment of new selective COX-2 inhibitors including methyl sulfonyl moiety. , 2020, European journal of medicinal chemistry.

[3]  N. Mohsin,et al.  Selective cyclooxygenase-2 inhibitors: A review of recent chemical scaffolds with promising anti-inflammatory and COX-2 inhibitory activities , 2020, Medicinal Chemistry Research.

[4]  C. La Motta,et al.  Synthesis, biological evaluation and molecular modeling of novel selective COX-2 inhibitors: sulfide, sulfoxide, and sulfone derivatives of 1,5-diarylpyrrol-3-substituted scaffold. , 2019, Bioorganic & medicinal chemistry.

[5]  Ş. Küçükgüzel,et al.  Synthesis, molecular docking and evaluation of novel sulfonyl hydrazones as anticancer agents and COX-2 inhibitors , 2019, Molecular Diversity.

[6]  Kimberly J. Jenko,et al.  2-(4-Methylsulfonylphenyl)pyrimidines as Prospective Radioligands for Imaging Cyclooxygenase-2 with PET—Synthesis, Triage, and Radiolabeling , 2018, Molecules.

[7]  A. Zarghi,et al.  Design, Synthesis and Biological Evaluation of New Imidazo[2,1-b]Thiazole Derivatives as Selective COX-2 Inhibitors , 2018, Iranian journal of pharmaceutical research : IJPR.

[8]  G. Rosell,et al.  Synthesis and biological properties of aryl methyl sulfones. , 2018, Bioorganic & medicinal chemistry.

[9]  R. Gundla,et al.  Molecular hybrid design, synthesis and biological evaluation of N-phenyl sulfonamide linked N-acyl hydrazone derivatives functioning as COX-2 inhibitors: new anti-inflammatory, anti-oxidant and anti-bacterial agents , 2017 .

[10]  R. Gundla,et al.  New Anti‐Inflammatory Hybrid N‐Acyl Hydrazone‐Linked Isoxazole Derivatives as COX‐2 Inhibitors:Rational Design, Synthesis and Biological Evaluation , 2017 .

[11]  F. Aiello,et al.  Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016). , 2017, MedChemComm.

[12]  Khaled R. A. Abdellatif,et al.  Design, synthesis, cyclooxygenase inhibition and biological evaluation of new 1,3,5-triaryl-4,5-dihydro-1H-pyrazole derivatives possessing amino/methanesulfonyl pharmacophore. , 2017, Bioorganic chemistry.

[13]  T. Tok,et al.  Synthesis and molecular modeling studies of naproxen-based acyl hydrazone derivatives , 2015 .

[14]  L. Cavaş,et al.  Synthesis of new ibuprofen derivatives with their in silico and in vitro cyclooxygenase-2 inhibitions. , 2014, Bioorganic chemistry.

[15]  James R Kiefer,et al.  The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life. , 2010, Bioorganic & medicinal chemistry letters.

[16]  R. DuBois,et al.  Eicosanoids and cancer , 2010, Nature Reviews Cancer.

[17]  Lawrence J Marnett,et al.  Structural and functional basis of cyclooxygenase inhibition. , 2007, Journal of medicinal chemistry.

[18]  N. V. Chandrasekharan,et al.  COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Jianxiong Jiang,et al.  Cyclooxygenase-2 in glioblastoma multiforme. , 2017, Drug discovery today.

[20]  Andleeb Shahzadi,et al.  Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma , 2015, Journal of Neuro-Oncology.

[21]  M. Noolvi,et al.  Synthesis and biological evaluation of 2-trifluoromethyl/sulfonamido-5,6-diaryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles: a novel class of cyclooxygenase-2 inhibitors. , 2008, Bioorganic & medicinal chemistry.

[22]  G. Trossini,et al.  Molecular Sciences Pharmacological Evaluation and Preparation of Nonsteroidal Anti-inflammatory Drugs Containing an N-acyl Hydrazone Subunit , 2022 .